Levosimendan Eg

Levosimendan, the active ingredient in Levosimendan Eg, is a calcium sensitizer / potassium channel opener presented as a strength/form for intravenous use. It treats acute decompensated heart failure in adult patients who require rapid improvement of cardiac output. GNH USA supplies Levosimendan Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure syndromes where enhanced cardiac contractility and vasodilation are needed. - Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Severe chronic heart failure with low output: provides hemodynamic support when conventional therapy is insufficient. - Low cardiac output syndrome after cardiac surgery: stabilises haemodynamics during the postoperative period.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient blood pressure reduction. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Flushing: warm sensation and skin reddening. - Arrhythmia: non‑sustained ventricular ectopy.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: transient increase in transaminases. - Thrombocytopenia: reduced platelet count.

Levosimendan requires careful monitoring and specific safety considerations before and during administration. - Blood pressure monitoring: watch for significant hypotension. - Cardiac rhythm surveillance: detect arrhythmias promptly. - Renal impairment: adjust use in patients with reduced clearance. - Hepatic impairment: use cautiously in liver disease. - Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Concurrent inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - Potent vasodilators (e.g., nitroglycerin): may cause profound hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for additive blood pressure effects. - Beta‑blockers: assess heart rate and contractility. - Calcium channel blockers: observe for combined vasodilatory impact. - Anticoagulants (e.g., warfarin): monitor coagulation parameters.